1. Effect of jejunal infusion of bile acids on small bowel transit and fasting jejunal motility in man;Penagini, R.; Misiewicz, J.J.; Frost, P.G.;Gut,1988
2. Effect of ileal infusion of glycochenodeoxycholic acid on segmental transit, motility, and flow in the human jejunum and ileum;Penagini, R.; Spiller, R.C.; Misiewicz, J.J.; Frost, P.G.;Gut,1989
3. Human distribution and release of a putative new hormone, peptide YY. Gastroenterology 1985; location. If this is the case, such a reflex would not be reproducible in the present isolated 89;Adrian, T.E.; Ferri, G.L.; Bacarese-Hamilton, A.J.; Feussel, H.S.; Polak, J.M.; Blook, SR
4. Peptide YY adnormalities in model. Alternatively, PYY may cause the release of other inhibitory agents which are responsible gastrointestinal diseases;Adrian, T.E.; Savage, A.P.; Bacarese-Hamilton, A.J.; Wolfe, K.; Besterman, H.S.; Bloom, SR;Gastroenterology,1986
5. Read NW, Bloom SR. The ileal brake: ileal fat slows down small bowel transit and gastric for inhibiting motility. This is unlikely as the specific antagonist PYX 1 failed to reverse bile mediated inhibition. Our studies suggest that the arrival of bile salts in the ileum may be one of the factors that stimulate the postprandial release of PYY, although the peptide does not seem to inhibit motility locally. Other regulatory peptides in the terminal ileum may mediate bile inhibition of ileal motility. VIP is localised to neurones in the emptying in man;Macfarlane, A.; Kinsman, R.,1983